Regulatory professionals operating within the European medical device landscape are encouraged to review the newly published Version 4 of the Manual on Borderline and Classification. This update, reflecting consensus agreements among EU Competent Authorities, is a critical regulatory resource designed to ensure the consistent interpretation and harmonised application of the Medical Device Regulation (MDR, EU 2017/745) and the In Vitro Diagnostic Medical Devices Regulation (IVDR, EU 2017/746) across all Member States.
Navigating the Borderline: New Qualification Case Examples
The manual’s core function is to provide clarity on the fundamental question of qualification, determining whether a product falls under the MDR/IVDR or other regulatory frameworks (e.g. medicinal products, cosmetics, biocides, PPE, or general consumer goods).
Version 4 introduces several new borderline case examples that directly impact manufacturers and Notified Bodies, offering crucial distinctions for novel or ambiguous products. Key examples for qualification include:
- Red blood cell additive solutions containing adenine
- Dual action cream with menthol and capsaicin
- Lactose tablets for vaginal use
- Microabrasion dental stain removers
- Qualification of medical examination table covers
- Mobile sterile air system
These additions aim to preempt regulatory divergence and provide a clear basis for initial product scoping and regulatory strategy.
Updated Classification Rules: Significant Changes to Device Class
Beyond qualification, the manual addresses the essential step of classification, detailing significant updates and clarifications to how certain device types are categorised under the MDR:
- Dermal fillers.
- nBCA adhesives for varicose veins.
- Custom-made cranial implants.
- Argon coagulation units.
- Ethylene oxide gas cartridges.
These updates demand an immediate re-evaluation of technical documentation and quality management systems for affected device manufacturers.
Scientific Evidence
A significant theme reinforced in Version 4 is the explicit reliance on scientific evidence for determining both product qualification and subsequent classification.
The manual emphasises that decisions must be grounded in robust, objective data rather than relying solely on manufacturer claims regarding a product’s intended purpose. This principle further pressures manufacturers to maintain high-quality clinical and non-clinical data to substantiate their regulatory submissions.
In summary, the release of Version 4 is a decisive step toward regulatory stability and predictability in the EU market. Regulatory affairs professionals must ensure these new consensus positions are promptly integrated into ongoing product development, documentation updates, and Notified Body interactions to maintain full compliance with MDR and IVDR requirements.